129-LB: Evaluation of Attitudes towards Two Glucagon Delivery Devices for Rescue Treatment of Severe Hypoglycemia

Abstract

Objective: This study assessed preference, hesitation using, perceived ease of use, and feeling prepared and protected for nasal glucagon (NG) vs. autoinjector glucagon (AI) for rescue treatment of severe hypoglycemia (SH) among people with diabetes (PWDs), caregivers (CGs) and acquaintances (AQs). Methods: US PWDs (type 1 or 2, on insulin; n=405), CGs (n=313) and AQs (n=305) completed an online survey, after viewing a description of SH and graphics and descriptions of NG and AI (based on publicly available information at the time of study; prior to access to the final commercial device or their instructions for use). Respondents rated strength of preference for NG vs. AI on 16 attributes using direct elicitation (7-point scale; 1 = ‘very strongly prefer AI‘ and 7 = ‘very strongly prefer NG’, 4 = neutral); 4 items focused on overall preference, being less likely to hesitate using, perceived ease of use, and feeling prepared and protected, and 12 items were averaged to create a preference scale (e.g., size of device, less complicated). This measure was developed using established guidelines for instrument development, including qualitative research and assessment of the measure’s psychometric properties. One sample t-tests evaluated whether mean preference ratings differed from a neutral score. Results: Across PWDs, CGs, and AQs, NG was preferred over AI (all P<0.001 compared to neutral) on overall preference (4.5, 4.9, and 5.4, respectively), being less likely to hesitate using (4.8, 5.1, and 5.4, respectively), perceived ease of use (4.8, 5.1, and 5.4, respectively) and the preference scale (4.7, 5.0, and 5.3, respectively). CGs and AQs preferred NG vs. AI on feeling prepared and protected (4.6 and 4.8, respectively; both P<0.001 compared to neutral); PWDs were neutral (4.1, P=0.376). Conclusions: This study provides insights on PWDs’, CGs’ and AQs’ attitudes towards new glucagon devices, which may be considered when making product choices among the glucagon delivery systems. Disclosure S.K. Bajpai: Employee; Self; Eli Lilly and Company. J. Cambron-Mellott: Other Relationship; Self; Eli Lilly and Company. N.K. Raibulet: Employee; Self; Eli Lilly and Company. E.Y. Peck: None. J. Poon: Employee; Self; Eli Lilly and Company. Q. Wang: Employee; Self; Eli Lilly and Company. B. Mitchell: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. O. Will: Other Relationship; Self; Eli Lilly and Company. J. Babrowicz: Other Relationship; Self; Eli Lilly and Company. C.J. Child: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. K. Beusterien: Other Relationship; Self; Eli Lilly and Company.